Introduction
The Bcl-2 family of genes codes for proteins that contain anti-apoptotic or pro-apoptotic activity. The cellular proteins of the BCL-2 family with antiapoptosis activity include BCL-2 (Korsmeyer, 1992; Reed, 1994) , BCL-x L (Boise et al., 1993) , MCL-1 (Reynolds et al., 1994) , NR-13 (Mangeney et al., 1996) and BFL-1 (D' Sa-Eipper et al., 1996) . Several viral homologs such as Epstein Barr virus-BHRF1 (Henderson et al., 1993; Takayama et al., 1994; Tarodi et al., 1994) , adenovirus E1B-19kDa Tarodi et al., 1993) , KSBCL-2/ORF 16 of HHV-8 (Russo et al., 1996; Cheng et al., 1997) and Herpes virus saimiri ORF 16 (Smith, 1995; Nava et al., 1997) also promote cell survival. In contrast, several BCL-2 family members which share one or more conserved domains, promote cell death. These pro-apoptotic members include BAX (Oltvai et al., 1993) and BAK (Chittenden et al., 1995a; Farrow et al., 1995; Kiefer et al., 1995) which are more closely related to the founding member, BCL-2, while BIK Han et al., 1996) , BID and HRK (Inohara et al., 1997) are more distantly related and share only a single domain with BCL-2.
In addition to the well-known apoptosis-regulatory activity, the BCL-2 family members also appear to possess several other related and unrelated activities. BCL-2 has been shown to cooperate with dominant oncogenes such as c-myc (Vaux et al., 1988; Strasser et al., 1990) and adenovirus E1A (Rao et al., 1992 ., D'SaEipper et al., 1996 Theodorakis et al., 1996; Uhlmann et al., 1996) . It is generally believed that the oncogene cooperative activity of BCL-2 is related to the antiapoptotic activity. A recent mutational analysis of EBV-BHRF1 has unmasked a proliferation-restraining activity (Theodorakis et al., 1996) . Other studies have also revealed such an activity associated with BCL-2 (Uhlmann et al., 1996; Vairo et al., 1996; O'Reilly et al., 1996; Borner et al., 1994) . It appears that the proliferation-restraining activity of BCL-2 may be distinct from the anti-apoptotic activity (Uhlmann et al., 1996; Vairo et al., 1996; Huang et al., 1997) . In contrast to the proliferation-restraining activity, BCL-2 has also been shown to possess a proliferationpromoting function in the central nervous system . In addition, certain anti-apoptotic members such as EBV-BHRF1 and mouse A1 have also been reported to play a role in cellular dierentiation. BHRF1 appears to disturb differentiation of epithelial cells (Dawson et al., 1995) while A1 has been shown to promote dierentiation of myeloid cells (Lin et al., 1996) . BCL-2 was not able to promote dierentiation of myeloid cells under the same conditions. Thus, BCL-2 family members appear to modulate other cellular processes in addition to apoptosis and in some cases this activity may be unique to certain members. The solution and crystallographic structures of BCL-x L has recently been determined and has been shown to resemble the structures of certain bacterial toxins that form membrane pores (Muchmore et al., 1996) . Consistent with this prediction, both BCL-x L and BCL-2 have been shown to form membrane pores in vitro (reviewed by Reed, 1997) . However, it is unclear how this characteristic relates to the multiple activities encoded by these proteins.
The human B¯-1 gene was discovered by data bank searches of expressed sequence tags (Choi et al., 1995) . Subsequently, an identical human cDNA (designated human A1) was also identi®ed as a TNF-inducible transcript (Karsan et al., 1996a) and was shown to protect endothelial cells against TNF-induced cell death (Karsan et al., 1996b) . The BFL-1 protein shares about 72% amino acid identity with mouse A1 protein and therefore both proteins may be considered homologs. Another BCL-2 family member, designated GRS, closely related to BFL-1 (diering in two amino acid positions) has also been identi®ed (Kenny et al., 1997) . BFL-1 and GRS are abundantly expressed in normal bone marrow cells and leukocytes and are activated in certain tumors such as gastrointestinal tumors (Choi et al., 1995) and hematopoietic malignancies (Kenny et al., 1997) . We have previously reported that B¯-1 eciently suppresses apoptosis and exhibits a potent oncogene cooperating activity (D'SaEipper et al., 1996) . BFL-1 is one of the smallest members (175 amino acids) of the BCL-2 family with anti-apoptotic activity and therefore oers a convenient model to study structure-function relationships. BFL-1 shares two highly conserved domains, BH1 and BH2 (Oltvai et al., 1993) and the recently recognized BH3 domain Chittenden et al., 1995b; Zha et al., 1996) , with other BCL-2 family proteins (Figure 1 ). Despite these homologies, BFL-1 does not contain a well-de®ned C-terminal transmembrane domain which is characteristic of most BCL-2 family proteins. Further, BFL-1 lacks a domain designated as NH1 that is essential for the anti-apoptotic activity of adenovirus E1B-19 kDa protein , BCL-2 and EBV-BHRF1 (Theodorakis et al., 1996) . BFL-1 also appears to have a cryptic BH4 domain which is essential for the antiapoptosis activity of BCL-2 (Borner et al., 1994; Hunter et al., 1996; Hanada et al., 1995) , BCL-x L (Minn et al., 1995) and EBV-BHRF1 (Theodorakis et al., 1996) . However, the limited BH4 homology observed in BFL-1 does not extend to mouse A1. Interestingly, the N-terminal region of both BFL-1 and A1 contain several Gln residues. Thus BFL-1 and A1 Figure 1 Amino acid sequence alignment of anti-apoptotic BCL-2 family proteins and BFL-1 mutants. The various conserved domains (BH1 ± 4) and NH1 are indicated. The Gln residues at the N-terminal region of BFL-1 are underlined. The C-terminal transmembrane domains of BCL-2 and BHRF1 are underlined. The amino acid sequences indicated in brackets were replaced with Alanine-Serine (indicated by AS) or Alanine (indicated by A). The a helices (a 1-a7) corresponding to those of BCL-X L determined from crystallographic and NMR structural analyses (Muchmore et al., 1996) are indicated contain certain unique sequence features in addition to features shared with other BCL-2 family members. Here, we have carried out mutational analysis of BFL-1 to dissect the various functions and to determine the sequence requirements for these activities.
Results

Anti-apoptosis activity of BFL-1 mutants
To analyse the role of the conserved domains BH1, BH2 and BH3, we constructed three dierent twoamino acid substitution mutants, 87 ± 8, 139 ± 40 and 52 ± 3, involving the most conserved residues ( Figure  1) . Similarly, three dierent mutations within the Nterminal region that includes the putative BH4 domain were constructed. One of these mutants involves a conserved Arg residue (mutant 11 ± 2) within the BH4 domain. The other two mutants involve the various Gln residues (mutants 18,22 and 38,45) . Although BFL-1 does not appear to contain a well-de®ned transmembrane domain like most other BCL-2 family proteins, we also constructed a deletion mutant (D152 ± 75) lacking the C-terminal region (residues 152 ± 175) that corresponds to the transmembrane c Figure 2 Eect of wt BFL-1 and mutants on p53-induced apoptosis. BRK-p53val135-E1A cells were transfected with various plasmids, G418 resistant colonies were pooled (38.58C) and survival at 32.58C was determined. Mutational analysis of BFL-1 C D'Sa-Eipper and G Chinnadurai domain of other family members such as BCL-2 and EBV-BHRF1. The anti-apoptotic activity of the various mutants was assayed employing cells that express a temperature sensitive mutant of the p53 tumor suppressor protein (Michalovitz et al., 1990) . Baby rat kidney (BRK) cells transformed with adenovirus E1a and a ts mutant of p53 (p53val135) express very high levels of the mutant p53 protein at the non-permissive (38.58C) temperature and undergo rapid apoptosis after the p53 protein assumes wt conformation at 32.58C (Debbas and White, 1993) . Others and we have previously used this assay system to analyse the anti-apoptosis activity of various BCL-2 family proteins (Chiou et al., 1994; Subramanian et al., 1995; D'Sa-Eipper et al., 1996; Theodorakis et al., 1996) . BRK-p53val135-E1A cells were transfected with the pcDNA3 vector or the various BFL-1 expression plasmids and G418 resistant colonies were selected at 38.58C. Comparable number of colonies (*50) were pooled and assayed for cell survival at 32.58C. Nearly all the cells transfected with the empty vector (pcDNA3HA) died within 72 h after shifting to 32.58C. In contrast, cells expressing wt BFL-1 did not signi®cantly lose viability during the 96 h assay period ( Figure 2a ). Cells transfected with mutants in the BH1 or BH2 domain died in a manner similar to that of cells transfected with empty vector, indicating that integrity of both BH1 and BH2 domains are crucial for the anti-apoptosis activity ( Figure 2a ). Mutation of residues 11 and 12 within the BH4 domain also signi®cantly aected the antiapoptosis activity, although the eect is somewhat less pronounced than that of mutations in the BH1 and BH2 domains ( Figure 2a) . Mutation of the conserved Leu (52) and Lys (53) residues of the BH3 domain (mutant 52 ± 3) induced only a slight reduction in the anti-apoptosis activity suggesting that the BH3 domain may not be critical for the cell survival activity (Figure 2a) . Deletion of the C-terminal region (mutant D 152 ± 75) reduced the cell survival by about 70% during the 96 h assay period suggesting that the C-terminal region corresponding to the transmembrane domain of other BCL-2 family members is required for full activity of BFL-1, but is not an absolute requirement (Figure 2b) .
Mutation of the Gln residues at positions 18 and 22 (mutant 18,22) and at positions 38 and 45 (mutant 38,45) exhibited interesting phenotypes. While mutant 38,45 exhibited somewhat reduced anti-apoptosis activity, mutant 18,22 appeared to exhibit a better anti-apoptosis activity compared to wt BFL-1 in short term (96 h) assays. This prompted us to examine the eect of mutant 18,22 on a long-term (192 h) cell survival assay. In this assay, mutant 18,22 clearly exhibited an enhanced anti-apoptosis activity and conferred an augmented survival advantage ( Figure  2c ). When cells expressing mutant 18,22 were maintained at 32.58C for an extended period of time, a large fraction of the cells remained viable and attached to the culture dish even after a 3 week incubation period (Figure 3 ; seen as specks throughout the culture¯ask after staining with Giemsa in Figure 3a , right panel; also as a uniformly distributed monolayer by microscopic examination in Figure 3b , right panel). In contrast, when cells expressing wt BFL-1 were maintained at 32.58C for an extended period of time, there was a gradual cellular degeneration leading to severe cells loss. A fraction of remaining viable cells formed proliferating colonies (Figure 3a and b left panels). Thus, mutant 18,22 appears to be a gain-of function mutant with enhanced anti-apoptosis activity by virtue of its ability to confer enhanced cell survival.
To determine if the activities of the mutants are due to any dierential levels of protein expression and/or subcellular localization, we analysed the expression of the mutant proteins by Western-blot analysis ( Figure  4a ) and by immuno¯uorescence analysis (Figure 4b ). Functionally defective mutants 11 ± 2 (BH4), 87 ± 8 (BH1) and 139 ± 40 (BH2) were found to be expressed at lower levels compared to wt BFL-1 while all other mutants were expressed at levels comparable to the wt level. Analysis of individual clones of the functionally defective mutants expressing levels of protein comparable to that of wt BFL-1 indicated that the near total functional defect may not be entirely attributed to lower levels of protein expression (data not shown). In the immuno¯uorescence analysis, all the mutants including the deletion mutant lacking the C-terminal region produced proteins that are concentrated in the nuclear envelope and endoplasmic reticulum. However, the proteins coded by the functionally defective mutants and the C-terminal deletion mutant exhibited a more diused localization around the nuclear envelope/endoplasmic reticulum regions. Since all mutant proteins appear to localize in the general subcellular regions where the wt BFL-1 localizes, we believe that the functional defect of the mutants described here may also not be fully attributable to defects in subcellular localization. Cell proliferation A characteristic feature of several BCL-2 family members such as BCL-2 and EBV-BHRF1 is that they promote cell survival, which is accompanied by a growth arrest. We have shown that the anti-apoptosis and the proliferation-restraining activities of BHRF1 and BCL-2 are separable and certain mutations in the BH3 and the non-conserved regions of BHRF1 (located between BH3 and BH4 domains) (Theodorakis et al., 1996) as well as the non-conserved region of BCL-2 (Uhlmann et al., 1996) relieve the proliferationrestraining activities of these proteins. During the above mentioned long-term cell survival assay, we observed that although most of the cells expressing wt BFL-1 died after incubation at 32.58C for an extended period, a fraction of the cells started to proliferate and formed visible colonies in about three weeks (Figure 3a and b, left panels). As shown in Figure 2 , none of the BFL-1 mutants exhibited enhanced cell proliferation in the short-term cell culture assays. In addition to the short-term assay, we also carried out a long-term assay where cells were maintained at 32.58C for an extended time period (3 weeks). Under this assay condition, we have previously observed that cells expressing wt BHRF1 or BCL-2 do not form proliferating colonies while only mutants that relieve the proliferation restraining activity, induce colony formation (Theodorakis et al., 1996 , Uhlmann et al., 1996 . When we carried out a similar long-term assay with cells expressing wt BFL-1, we observed a signi®cant number of proliferating colonies (Figure 5a ). Immunoblot analysis indicates that these cells continue to express wt BFL-1 (Figure 6a ) and high levels of p53 at both 37.58C and 32.58C (Figure 6b) . Thus, our results suggest that BFL-1, unlike BCL-2 and BHRF1, may lack a proliferation restraining activity. In contrast to cells expressing wt BFL-1, mutants 11 ± 2 (BH4), 87 ± 8 (BH1) and 139 ± 40 (BH2) did not induce a detectable number of colonies (Figure 5b ). Mutants involving Gln residues at the N-terminal region (mutant 18,22, Figure  3a , right panel and mutant 38,45, Figure 5a ) and the Figure 5a ) induced much reduced number of colonies ( Figure 5b ). Mutant 52 ± 3 (BH3) induced comparable number of colonies as wt BFL-1. Since mutants in the Gln residues do not signi®cantly impair the anti-apoptotic activity, but appear to have impaired proliferation activity, it appears that the Gln residues may be speci®cally required for the proliferationpermitting activity.
Oncogene cooperation
We have previously reported that B¯-1 has a potent oncogene cooperating activity using the primary rat kidney (BRK) epithelial cells as the model system (D' Sa-Eipper et al., 1996) . Here we have examined the eect of the various B¯-1 mutants for their ability to transform BRK cells in cooperation with a model dominant oncogene, adenovirus E1a. For these studies, we chose the E1a oncogene since it is a well-studied dominant oncogene and exerts its transforming activity by modulating two converging pathways which involve two cellular proteins, p300 and pRb (reviewed in Nevins, 1992) . At least some aspect of E1a-mediated transformation may be ultimately linked to the cellular response to p53 (Wu and Levine, 1994) . BRK cells prepared from two-day old neonatal rats were transfected with pE1A and either with pcDNA3 (empty vector) or pcDNA3HA-B¯-1. Transformed colonies were detected by G418 selection. Cells contransfected with pE1A and pcDNA3 vector produced a few slowly growing colonies. In contrast, cells contransfected with pcDNA3HA-B¯-1 and pE1A resulted in a number of rapidly growing foci (Figure Figure 6 Levels of BFL-1 (a) and p53 (b) in BRK-p53val135-E1A cells expressing wt BFL-1. Cells were examined for protein levels at both 38.58C and 32.58C by ®rst immunoprecipitating using either anti-HA monoclonal antibody or anti-p53 monoclonal antibody, followed by Western blotting using the same antibodies. MEF p53 7/7 indicates mouse embryo ®broblasts from p53 null mice Mutational analysis of BFL-1 C D'Sa-Eipper and G Chinnadurai 7a). The frequency of transformation by the BH3 mutant, 52 ± 3, was more or less similar to that of wt BFL-1 while the two mutants in the N-terminal Gln residues (mutant 18, 22 and 38, 45) and the C-terminal deletion mutant (D152 ± 75) induced cooperative transformation at a somewhat reduced frequency compared to wt BFL-1 (Figure 7b ). Mutants 11 ± 2 (BH4), 87 ± 8 (BH1) and 139 ± 40 (BH2) did not exhibit signi®cant oncogene cooperative activity. Among the various BFL-1 mutants tested, in general all the mutants that were positive in the anti-apoptosis assay were also positive in the transformation assay. We note that mutant 18, 22 does not show enhanced oncogene cooperation (compared to wt BFL-1) even though it exhibits an enhanced anti-apoptosis activity.
Discussion
We have carried out a detailed mutational analysis of BFL-1, one of the smaller anti-apoptotic members of the BCL-2 family. Our results indicate that the integrity of the conserved BH1, BH2 and BH4 domains are essential for the multiple activities encoded by B¯-1. In contrast, the conserved BH3 domain which is essential for the activity of pro-apoptotic proteins (Chittenden et al., 1995b; Boyd et al., 1995) may not be essential for these activities. This would be consistent with the observation that certain viral BCL-2 homologs such as ORF-16 of HHV-8 and Herpes virus saimiri do not contain recognizable BH3 domains (Smith, 1995; Russo et al., 1996; Cheng et al., 1997; Nava et al., 1997) . Mutations in the BH3 domain of EBV-BHRF1 also did not aect the anti-apoptosis activity (Theodorakis et al., 1996) . All mutants defective in the anti-apoptosis activity are also defective in the oncogene cooperation activity, suggesting that these two activities may be linked. In spite of this relationship, one of the Nterminal mutants, mutant 18,22 which exhibits an enhanced anti-apoptosis activity, does not cooperate with E1A more eciently than wt BFL-1. Since the eect of mutant 18,22 is more pronounced in terms of a qualitative eect (i.e., enhancing the period of viability) rather than a quantitative short term eect, it is possible that this mutation aects a distinct late step in apoptosis that is not required for the initiation of oncogenic transformation.
We have observed that mutagenization of two Gln residues within the BH4 domain enhances the antiapoptosis activity. Since Gln residues are implicated in protein-protein interaction (Mitchell and Tjian, 1989) , it is possible that the N-terminal region of BFL-1 may interact with other proteins that may negatively modulate the anti-apoptosis activity of BFL-1. The BH4 domain of BCL-2 has been shown to interact with BAG-1 (Takayama et al., 1995) and calcineurin (Shibasaki et al., 1997) . Although we have not determined that these proteins interact with BFL-1, it is possible that the Gln-rich region of the N-terminus of BFL-1 interacts with these or other as yet unknown proteins. The mutant 18,22 may alter normal BFL-1 interaction with unknown partners and thus aect its anti-apoptosis activity. We have also observed that the pattern of interaction of mutant 18,22 with various pro-apoptotic proteins such as BIK, BAK and BID is similar to wt BFL-1 (not shown).
Unlike certain other members (e.g., BCL-2 and EBV-BHRF1), expression of BFL-1 permits cell proliferation over an extended period of time. It is interesting that this proliferation occurs even in the presence of elevated levels of functionally wt p53. This activity of BFL-1 may have an important implication in oncogenesis. Since BFL-1 and the related protein GRS, are overexpressed in several human malignancies of epithelial (Choi et al., 1995) and hematopoietic origin (Kenny et al., 1997) , the proliferation facilitating activity in addition to its antiapoptosis activity may contribute to the ontogeny of some of these malignancies. The proliferation facilitating activity of wt BFL-1 that we have discovered here, contributes to the enhanced in vitro oncogene cooperating activity (compared to other BCL-2 family members) that we have reported earlier . It is interesting that mutant 18,22 which exhibits an enhanced anti-apoptosis activity also exhibits a much reduced proliferation facilitating activity. Similarly, mutant 38,45 involving two other Gln residues also exhibits a greatly reduced proliferation activity and only a modest reduction in the anti-apoptosis activity. Although mutants in the BH1, BH2 and BH4 domains are also defective in the proliferation facilitating activity, it is possible that their eect may be global due to their eect in the overall structure of BFL-1 as suggested by the solution and crystallographic structure of BCL-x L (Muchmore et al., 1996) . Thus, mutant 18,22 facilitates separation of the anti-apoptosis and the proliferation facilitating activity. This mutant may provide a valuable tool to identify putative factors that may modulate cell proliferation in cooperation with BCL-2 family proteins.
Although the C-terminal region of BFL-1 does not conform to the sequence requirements of the TM as in the case of other BCL-2 family members, it appears to be required for ecient activity of BFL-1. As in the case of BCL-2 (Hockenbery et al., 1990) , deletion of the C-terminal 24 residues reduced the cell survival activity of BFL-1. Deletion of the C-terminal region also reduced other activities of BFL-1. These results are in contrast to the eect of a similar mutation in EBV-BHRF1 in which the TM region appears to be absolutely essential under similar assay conditions (Theodorakis et al., 1996) . These observations suggest that internal regions of certain BCL-2 family members may be directly or indirectly involved in subcellular targeting. For example, BCL-2 mutants lacking the TM appear to be fully functional under certain assay conditions while a comparable mutant that also deletes the internal non-conserved region has been shown to functionally defective (Hunter et al., 1996) . Since BFL-1 lacking the C-terminal region appears to localize more-or-less in the same regions as wt BFL-1, it is possible that certain internal sequences of BFL-1 may also be involved in subcellular localization.
The mutational analysis of BFL-1 presented in this paper has facilitated dissection of the multiple activities encoded by this protein, thus establishing a correlation between the anti-apoptosis activity and oncogene cooperation activity and has facilitated recognition of a novel proliferation facilitating activity associated with the N-terminal region. Some of the mutants described here may provide important tools to uncover a possible relationship between cell proliferation and control of apoptosis.
Materials and methods
Plasmids and mutants
The wild type BFL-1-expressing plasmid pcDNA3HA-B¯-1 has been described in D' Sa-Eipper et al. (1996) . The various B¯-1 mutants were generated by PCR mutagenesis. For mutants 11 ± 2, 52 ± 3, 87 ± 8 and 139 ± 40, the amino acids indicated in brackets in Figure 1 were replaced by alanine-serine (indicated by AS) (encoded by an NheI site). For mutants 18,22 and 38,45 the glutamines underlined were replaced with alanine. Mutant D152 ± 75 lacks the Cterminal 24 amino acids of BFL-1. All mutants were cloned into the pcDNA3HA vector .
Cell lines
The BRK-p53val135-E1A cell line has been described and was maintained at 38.58C in Dulbecco's modi®ed Eagle medium (DMEM) supplemented with 10% fetal calf serum. BRK-p53val135-E1A cells stably expressing BFL-1 or the various mutants were generated by transfection of pcDNA3-based expression plasmids and selection with G418 (250 mg/ml). DNA transfections were carried out by the standard calcium phosphate method.
Cell death assays
BRK-p53val135-E1A cells were plated at 5610 5 cells/ 60 mm dish. After 24 h at 38.58C, the dishes were shifted to 32.58C. At various intervals cells were trypsinized in triplicates, stained with 0.2% trypan blue and viable cells were counted.
Western blotting
5610
6 BRK-p53val135-E1A cells expressing BFL-1 or the various mutants were lysed in isotonic buer (150 mM NaCl, 50 mM Tris (pH 8.0), 1% NP40, 0.5% sodium deoxycholate and 0.1% SDS) containing protease inhibitors (0.04 mg/ml aprotinin, 0.2 mg/ml leupeptin and 200 mM PMSF). Lysates (clari®ed by 30 min microcentrifugation) were precleared with protein A-Sepharose for 1 h, which was removed by centrifugation. The proteins were immunoprecipitated with an anti-HA monoclonal antibody (12CA5; Boehringer Mannheim), run on a SDS polyacrylamide gel and transferred to a nitrocellulose membrane. The membrane was then probed with anti-HA monoclonal antibody at 2.5 mg/ml followed by incubation with horseradish-peroxidase-conjugated protein A (Amersham LIFE SCIENCE) and detection using enhanced chemiluminescence (Amersham LIFE SCIENCE). Antip53 monoclonal antibody (AB-1; Oncogene Science) was used in the analysis of p53 protein levels.
Immuno¯uorescence
Cells were ®xed in 3.7% formaldehyde and permeabilized in ice-cold methanol. They were then stained with anti-HA monoclonal antibody (12CA5; Boehringer Mannheim) and counterstained with¯uorescein conjugated anti-mouse antibody (Pierce).
